Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.55 |
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.47 |
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.44 |
| ▸ | PPARG known ✓ | P37231 | 2/20 | 0.44 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11896891 | 1.00 | CA2 (0.55) | CA2MEN1KMT2ANPC1TP53 | |
| SCHEMBL1225145 | 0.98 | CA2 (0.56) | CA2MEN1KMT2ANPC1TP53 | |
| SCHEMBL13223715 | 0.98 | CA2 (0.56) | CA2MEN1KMT2ANPC1TP53 | |
| SCHEMBL15092902 | 0.98 | CA2 (0.56) | CA2MEN1KMT2ANPC1TP53 | |
| SCHEMBL10941514 | 0.87 | SLC7A5 (0.54) | CA2MEN1KMT2ANPC1TP53 | |
| SCHEMBL19368953 | 0.86 | KMT2A (0.49) | CA2MEN1KMT2ANPC1TP53 | |
| SCHEMBL16684123 | 0.85 | CA2 (0.49) | CA2MEN1KMT2ANPC1TP53 | |
| SCHEMBL561161 | 0.84 | CA2 (0.57) | CA2MEN1KMT2ANPC1TP53 | |
| SCHEMBL561160 | 0.84 | CA2 (0.57) | CA2MEN1KMT2ANPC1TP53 | |
| SCHEMBL15604856 | 0.84 | CA2 (0.55) | CA2MEN1KMT2ANPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073882-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-07-07 | — | — | US | disclosed |
| US-8580921-B2 | Protein nanorings | UNIVERSITY OF MINNESOTA (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130059359-A1 | Protein Nanorings | UNIVERSITY OF MINNESOTA (US) | 2013-03-07 | — | — | US | disclosed |
| US-8236925-B1 | Protein nanorings | UNIVERSITY OF MINNESOTA (US) | 2012-08-07 | — | — | US | disclosed |
| US-20060264643-A1 | One Pot Synthesis of 2-Oxazolidinone Derivatives | ASTRAZENECA UK LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1227095-B1 | A process for the purification of (S)-4-((3-(dimethylamino)ethyl)-1H-indol-5yl)-methyl)-2-oxazolidinone | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20050187274-A1 | One pot synthesis of 2-oxazolidinone derivatives | PATEL RAJNIKANT (GB) | 2005-08-25 | — | — | US | disclosed |
| US-6909005-B1 | One post synthesis of 2-oxazolidinone derivatives | ASTRAZENECA UK LIMITED (GB) | 2005-06-21 | — | — | US | disclosed |
| EP-0843672-B1 | ONE POT SYNTHESIS OF 2-OXAZOLIDINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-13 | — | — | EP | disclosed |
| EP-1227095-A2 | A process for the purification of (S)-4-((3-(dimethylamino)ethyl)-1H-indol-5yl)-methyl)-2-oxazolidinone | AstraZeneca AB (SE) | 2002-07-31 | — | — | EP | disclosed |
| US-5099069-A | Radioactive materials for diagnosis and treatment of tumors and cancer by joining monoclonal antibodies | GANSOW OTTO A (US) | 1992-03-24 | — | — | US | disclosed |
| EP-0328529-A4 | BACKBONE POLYSUBSTITUTED CHELATES FOR FORMING A METAL CHELATE-PROTEIN CONJUGATE | — | 1991-03-20 | — | — | EP | disclosed |
| EP-0355860-A1 | A bifunctional metal chelating agent and a precursor compound | GANSOW, Otto A. (US) | 1990-02-28 | — | — | EP | disclosed |
| EP-0328529-A1 | METHOD FOR PREPARING POLYSUBSTITUTED DIETHYLENETRIAMINEPENTAACETIC ACIDS. | GANSOW OTTO A (US) | 1989-08-23 | — | — | EP | disclosed |
| US-4831175-A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0315220-A1 | Method of forming a metal chelate protein conjugate | GANSOW, Otto A. (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4824986-A | Metal chelate protein conjugate | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1989-04-25 | — | — | US | disclosed |
| WO-1988001618-A1 | BACKBONE POLYSUBSTITUTED CHELATES FOR FORMING A METAL CHELATE-PROTEIN CONJUGATE | GANSOW OTTO A (US) | 1988-03-10 | — | — | WO | disclosed |
| EP-0220279-A1 | METHOD OF FORMING A METAL CHELATE PROTEIN CONJUGATE | GANSOW, Otto A. (US) | 1987-05-06 | — | — | EP | disclosed |
| WO-1986006384-A1 | METHOD OF FORMING A METAL CHELATE PROTEIN CONJUGATE | GANSOW OTTO A (US) | 1986-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264643-A1 | One Pot Synthesis of 2-Oxazolidinone Derivatives | AZI2, INTS6, NISCH | CA2 299/4885ACE 369/4885MMP1 3235/4885 |
| US-20050187274-A1 | One pot synthesis of 2-oxazolidinone derivatives | AZI2, INTS6, NISCH | CA2 324/4885ACE 406/4885MMP1 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.